$107.11
0.04%
NYSE, Nov 16, 04:00 pm EST. Closed.
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Stock News

Neutral
●
Business Wire
●
12 days ago
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026. Q3 Financial Highlights Q3 sales grew 10.5% to $1.72 billion1, constant currency2 sales grew 11.2% Q3 TAVR sales grew 8.0% to $1.24 billion1, constant currency2 sales grew 8.8% Q3 TMTT sales grew 44.0% to $207 million1,3, constant currency2 sales grew 45.6%...
Neutral
●
Business Wire
●
14 days ago
SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of the CLASP II TR trial. The evidence further showed significant reduction of tricuspid regurgitation (TR) and substantially improved health status, both sustained throug...
Neutral
●
Business Wire
●
14 days ago
SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial demonstrated that transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance in the primary composite endpoint of death or heart failure events at two years in moderate AS patie...
Positive
●
Market Watch
●
26 days ago
Investors have pushed the healthcare sector to a record high, and some favored stocks have high projected revenue growth rates through 2028.
Neutral
●
Business Wire
●
27 days ago
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy who are deeme...
Neutral
●
Business Wire
●
about one month ago
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team. A live webcast of the event will be available on the ...
Neutral
●
Business Wire
●
about 2 months ago
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement. For many pediatric patients, pulmonary valve replacement is not a one-time eve...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today